Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats

Coronavirus disease 2019 (COVID-19), caused by a new strain of coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide. Nafamostat mesylate (NFM) suppresses transmembrane serine protease 2 and SARS-CoV-2 S protein-mediated fusion. In this study...

Full description

Bibliographic Details
Published in:	Pharmaceutics
Main Authors:	Ji-Hyun Kang, Young-Jin Kim, Min-Seok Yang, Dae Hwan Shin, Dong-Wook Kim, Il Yeong Park, Chun-Woong Park
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Subjects:	COVID-19 nafamostat mesylate dry powder inhaler lecithin mannitol co-spray
Online Access:	https://www.mdpi.com/1999-4923/13/9/1519

Similar Items

Nafamostat mesylate augments survival in rats afflicted by exertional heat stroke
by: Qingwei Lin, et al.
Published: (2025-05-01)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
by: Weiwei Qian, et al.
Published: (2023-09-01)

Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study
by: Jiangtao Li, et al.
Published: (2025-12-01)

Comparison of circuit patency and exchange rates between the original and generic versions of nafamostat mesylate in critically ill adults receiving continuous renal replacement therapy
by: Sujung Heo, et al.
Published: (2023-03-01)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
by: Yuxin Zhang, et al.
Published: (2020-08-01)

Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
by: Pei Xie, et al.
Published: (2025-03-01)

Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy
by: Ma Xiaobo, et al.
Published: (2025-09-01)

Anticoagulation application of nafamostat mesylate in patients on continuous renal replacement therapy at a high risk of hemorrhage
by: Jia-rong Ding, et al.
Published: (2024-02-01)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
by: Wenli Guo, et al.
Published: (2022-11-01)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
by: Takahiro Hirayama, et al.
Published: (2017-07-01)

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes
by: Yiqi Qian, et al.
Published: (2024-09-01)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
by: Hyeon-A Kim, et al.
Published: (2022-06-01)

Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
by: Shinya Kameda, et al.
Published: (2024-02-01)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
by: Shinya Kameda, et al.
Published: (2023-01-01)

Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples
by: Dong Hwan Lee, et al.
Published: (2025-05-01)

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study
by: Dan Liu, et al.
Published: (2024-01-01)

Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway
by: Weili Liao, et al.
Published: (2025-10-01)

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report
by: Yasuhito Suzuki, et al.
Published: (2024-01-01)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
by: Hyeon Seok Oh, et al.
Published: (2022-03-01)

Development of Mannitol-Based Microparticles for Dry Powder Inhalers: Enhancing Pulmonary Delivery of NSAIDs
by: Petra Party, et al.
Published: (2025-06-01)

Optimization of Spray Drying Process Parameters for the Preparation of Inhalable Mannitol-Based Microparticles Using a Box-Behnken Experimental Design
by: Jakub Karas, et al.
Published: (2023-02-01)

Measuring the Concentration of Serum Syndecan-1 to Assess Vascular Endothelial Glycocalyx Injury During Hemodialysis
by: Keigo Kusuzawa, et al.
Published: (2021-12-01)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
by: Megan Neary, et al.
Published: (2023-08-01)

The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites
by: Antony Cheudjeu
Published: (2022-03-01)

Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial
by: Hongyu Yang, et al.
Published: (2025-07-01)

Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice
by: Hirofumi Matsubara, et al.
Published: (2022-01-01)

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
Published: (2009-09-01)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
by: Gwanyoung Kim, et al.
Published: (2023-09-01)

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats
by: Hugo Juárez Olguín, et al.
Published: (2009-08-01)

Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate
by: Qiaolan He, et al.
Published: (2024-10-01)

STUDY OF WAYS TO REDUCE THE VISCOSITY OF SUNFLOWER LECITHIN
by: A. Demydova, et al.
Published: (2023-07-01)

Mannitol Polymorphs as Carrier in DPIs Formulations: Isolation Characterization and Performance
by: Ayça Altay Benetti, et al.
Published: (2021-07-01)

A Novel Cleavage Pattern of Complement C5 Induced by Chlamydia trachomatis Infection via the Chlamydial Protease CPAF
by: Liang Peng, et al.
Published: (2022-01-01)

EFFECT OF SOME FACTORS ON THE PRODUCTION OF MANNITOL FROM Lactobacillus brevis
by: W. A. Mahmood, et al.
Published: (2013-04-01)

Low-dose nafamostat mesilate ameliorates tissue injury and inhibits 5-hydroxytryptamine synthesis in the rat intestine after methotrexate administration
by: Takahiro Yamamoto, et al.
Published: (2023-06-01)

Commentary on “time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in a new antibacterial agent: alalevonadifloxin mesylate”
by: D. J. Snodin, et al.
Published: (2020-11-01)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
by: Yao Lin, et al.
Published: (2022-12-01)

Encapsulation of Alcohol Dehydrogenase in Mannitol by Spray Drying
by: Hirokazu Shiga, et al.
Published: (2014-03-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity
by: Shulin Hou, et al.
Published: (2025-08-01)